Combination of anti-HER2 breast cancer therapy and checkpoint inhibitor provides no b

[News]

Adding an immune checkpoint inhibitor to anti-HER2 treatment in breast cancer does not improve pathological complete response (pCR), according to the primary analysis of the IMpassion050 trial presented today during the ESMO Virtual Plenary.

More... (https://www.news-medical.net/news/20210618/Combination-of-anti-HER2-breast-cancer-therapy-and-checkpoint-inhibitor-provides-no-benefit.aspx)